Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
NCT05352763
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
90
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor Decision
Conditions
Alzheimer's Disease
Interventions
DRUG:
simufilam
Sponsor
Cassava Sciences, Inc.